By Budi Oetomo Narendra 
Breast cancer screening, while undeniably a life-saving intervention, has long contended with the complex phenomenon of overdiagnosis. This occurs when screening identifies a cancer that, had it gone undetected, would never have caused symptoms or threatened a woman’s health during her lifetime. For decades, this aspect has been considered a substantial drawback, fostering considerable debate among researchers, clinicians, and public health officials globally regarding the true balance of benefits and harms in population-based screening programs.
A groundbreaking new study, spearheaded by researchers from the University of Southern Denmark, Lillebælt Hospital, the University of Copenhagen, and Queen Mary University of London, offers a significant recalibration of these long-standing estimates. By meticulously re-evaluating data from all major randomized controlled trials (RCTs) of mammography screening and comparing them with real-world insights from Denmark, the study concludes that the extent of overdiagnosis in breast cancer screening is likely far lower than previous, widely cited figures suggested. While some earlier analyses from randomized trials hinted at overdiagnosis rates as high as 30-50% of screen-detected cancers, this comprehensive new analysis aligns with estimates below 5%, drastically altering the landscape of this critical discussion.
Decades of Debate: The Enigma of Overdiagnosis
The concept of overdiagnosis in breast cancer screening is not new; it has been a contentious point in medical literature and public health discourse for many years. Screening, by its very nature, aims to detect disease at an early, often asymptomatic stage. In the context of breast cancer, this early detection through mammography has been instrumental in reducing mortality rates by enabling timely treatment. However, the biological spectrum of breast cancer is broad, encompassing aggressive, fast-growing tumors alongside slow-growing or indolent lesions that may never progress to cause harm. It is this latter category that forms the basis of overdiagnosis.
The challenge lies in distinguishing between these two types of cancers at the point of diagnosis. Without this ability, all screen-detected cancers are typically treated, leading to unnecessary interventions—such as surgery, radiation, and chemotherapy—for women whose lives would not have been impacted by their disease. The implications of overdiagnosis are profound, ranging from the psychological distress of a cancer diagnosis, the physical side effects of treatment, to the significant financial burden on healthcare systems.
For decades, the high estimates of overdiagnosis, particularly those derived from some initial interpretations of randomized controlled trials, fueled arguments against widespread population-based screening or advocated for less frequent screening intervals. These figures influenced international discussions, shaped communication strategies for women considering screening, and contributed to a sense of unease about the potential downsides of what is otherwise a crucial public health initiative.
A New Look at Foundational Mammography Trials
"The aim of our study was to bring together the evidence from all randomized controlled trials to get a clearer picture of the extent of overdiagnosis in breast cancer screening," explains Sisse Helle Njor, a professor at the University of Southern Denmark and Lillebælt Hospital. She emphasizes the importance of this re-evaluation: "Randomized trials have often been cited as evidence that overdiagnosis is a substantial problem. Our study shows that this interpretation is not as straightforward as it may seem."
To achieve this clearer picture, the research team undertook an ambitious task: a combined re-analysis of results from all eight major randomized trials of mammography screening. These trials represent the bedrock of evidence for breast cancer screening efficacy, conducted over several decades and involving hundreds of thousands of women. The trials included:
- The New York Health Insurance Plan (HIP) Study
- Malmö Mammographic Screening Trial
- Two-County Trial (Sweden)
- Edinburgh Trial
- The Canadian National Breast Screening Study (CNBSS)
- Stockholm Mammographic Screening Trial
- Gothenburg Mammographic Screening Trial
- UK Age Trial
These studies, initiated between the late 1960s and early 1990s, were designed to compare breast cancer incidence and mortality in screened versus unscreened populations. While invaluable for establishing the mortality benefit of screening, their long-term data also became the primary source for estimating overdiagnosis. The present study meticulously revisited these datasets, applying a more nuanced analytical framework that accounts for crucial temporal dynamics and external influences.
The Danish Real-World Reference: A Chronological Insight
A key innovation of this new analysis was the integration of data from Denmark’s routine screening programs as a crucial "real-world" reference. Denmark presented a unique epidemiological laboratory due to the staggered introduction of organized breast cancer screening. In some regions, screening began as much as 17 years earlier than in others. This difference provided a natural experiment, allowing researchers to track the evolution of breast cancer diagnoses immediately after screening commenced and how these patterns developed over extended periods.
This staggered rollout proved invaluable for understanding the transient effects of screening introduction. "When screening is introduced, the number of breast cancer diagnoses initially rises because cancers are detected earlier than they would have been without screening," clarifies Elsebeth Lynge, professor emerita at the Department of Public Health, University of Copenhagen. "Over time, this should be followed by a drop, as some of these cancers would otherwise have been diagnosed later. This pattern can also be affected if women in either group continue to undergo screening after the trials had ended, which was common. If researchers do not take these factors into account, the initial increase can be mistaken for overdiagnosis."
By comparing breast cancer incidence at matching points in time in both the randomized trials and Denmark’s routine screening programs, the researchers could assess the similarities in patterns and, crucially, interpret what those similarities revealed about the true scale of overdiagnosis. The concordance found between the additional breast cancer cases detected in the randomized trials and the patterns observed in Denmark, where overdiagnosis associated with screening is estimated to be below 5%, was a pivotal finding.
The Critical Role of Timing: Unpacking Methodological Nuances
The central thesis of the new study revolves around the critical importance of "timing" in accurately estimating overdiagnosis. Screening fundamentally alters the temporal landscape of disease detection. When mammography is introduced, there is an immediate surge in diagnoses, a phenomenon often referred to as "lead-time bias." This initial rise reflects cancers being detected earlier than they would have been without screening.
The crucial insight is that this initial increase should, over sufficient follow-up time, be followed by a corresponding decline in diagnoses in the screened group compared to the control group. This decline represents the cancers that were "advanced" by screening but would eventually have become clinically apparent anyway. If a study concludes before this compensatory drop becomes visible, or if the follow-up period is insufficient, researchers may incorrectly attribute a portion of the early diagnostic surge to overdiagnosis.
Furthermore, estimates can be distorted by the subsequent screening of women in control groups. In many older randomized trials, women initially assigned to the control arm (no screening) later gained access to screening, either through organized programs or opportunistic screening. This "contamination" blurs the distinction between screened and unscreened populations over time, making it harder to precisely quantify the long-term effects of screening, including overdiagnosis.
The new analysis rigorously accounted for these factors: the duration of follow-up, the extent of screening exposure in both intervention and control groups, and the natural temporal shifts in diagnosis rates. "Taken together, we believe some previous high estimates of overdiagnosis, which influenced screening guidelines and communication, were based on evidence before trial data had fully matured," states Matejka Rebolj, Senior Epidemiologist at Queen Mary University of London. "When interpreted in their full temporal context, randomized trial data are consistent with overdiagnosis of less than five percent, rather than with estimates nearing 50%." This conclusion suggests that a significant portion of what was previously labeled as overdiagnosis might, in fact, be lead-time—cancers found earlier but still destined to become clinically relevant.
Implications for Public Health Policy and Patient Communication
The findings of this study carry profound implications for public health policy, particularly concerning national and international breast cancer screening guidelines. Organizations like the World Health Organization (WHO) and various national health bodies continually review the evidence base for screening programs, balancing the clear benefits of mortality reduction against potential harms, with overdiagnosis being a prominent concern. If the true rate of overdiagnosis is substantially lower than previously believed, it strengthens the overall risk-benefit profile of organized mammography screening programs.
This re-evaluation provides a robust scientific basis for public health authorities to reinforce the value of screening. It could lead to a renewed emphasis on the importance of regular screening for eligible women, potentially shifting the narrative away from a perceived significant risk of overdiagnosis towards a greater focus on the life-saving potential of early detection.
Equally critical are the implications for patient communication and shared decision-making. Women invited for screening are often presented with information about both the benefits (reduced mortality) and the harms (false positives, anxiety, and overdiagnosis). The prospect of being diagnosed and treated for a cancer that would never have caused harm is a legitimate and often distressing concern for many.
"Most women will not develop breast cancer, but with this study we can now be reassured that the benefits of detecting breast cancer early and preventing premature death will outweigh the small risk of unnecessary treatment," affirms Sisse Helle Njor. This reassurance can empower women to make more informed decisions, reducing anxiety associated with the "potential harm" aspect of screening. "With this in mind, we hope this study will provide a framework for a more realistic interpretation of the evidence and help us better inform women when they are invited for screening." The revised understanding of overdiagnosis allows healthcare providers to present a more balanced and encouraging perspective, emphasizing the net benefit of participation.
Broader Scientific Context and Future Directions
The study’s findings resonate within a broader scientific context that continually seeks to refine our understanding of breast cancer and its management. While the debate over overdiagnosis has been significant, it has also spurred innovation. Researchers are actively pursuing new technologies and biomarkers that could one day differentiate between aggressive cancers requiring immediate treatment and indolent lesions that might be safely monitored through "active surveillance." This includes advancements in artificial intelligence for mammography interpretation, genetic profiling of tumors, and more sophisticated risk stratification models.
This re-analysis of existing data underscores the ongoing value of rigorous epidemiological research and the importance of revisiting foundational evidence with refined methodologies. It highlights that scientific understanding is dynamic, and conclusions can evolve as new analytical tools emerge and as longer-term data matures.
The study examined both invasive breast cancer and ductal carcinoma in situ (DCIS), a non-invasive condition often considered a precursor to invasive cancer, and a significant contributor to overdiagnosis debates. The findings suggest that even for DCIS, the overdiagnosis rate may be lower than previously estimated when viewed through the lens of long-term follow-up and comprehensive data integration.
This research was made possible through the support of funding bodies, with Casper Urth Pedersen receiving support from the Novo Nordisk Foundation (reference: NNF22OC0076184), and Matejka Rebolj supported by Cancer Research UK (reference: C8162/A29083). Their work offers a critical update to a long-standing debate, providing a more optimistic outlook on the balance of benefits and harms in breast cancer screening and reinforcing its crucial role in public health. As healthcare systems strive for optimal patient care and resource allocation, a clearer, more accurate understanding of overdiagnosis is an invaluable step forward.
